Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women living with HIV in Africa are at particular risk. An effective prophylaxis regimen capable of preventing malaria and other common perinatal infections would have great potential to improve adverse birth outcomes. The purpose of this randomized controlled trial is to evaluate a new combination prophylaxis regimen in pregnant women with HIV in Cameroon to determine its efficacy and safety.
The World Health Organization (WHO) recommends malaria prophylaxis for all pregnant women living in endemic areas in order to reduce maternal anemia, low birth weight and perinatal mortality by 25-45%. The most commonly used regimen is intermittently dosed sulfadoxine-pyrimethamine (SP).Unfortunately, SP prophylaxis is contraindicated for HIV-infected pregnant women since co-administration with TMPS (trimethoprim-sulfamethoxazole) causes serious adverse events. TMPS (Bactrim or Cotrimoxazole) is an effective, well-tolerated, low-cost antibiotic that is used as prophylaxis in HIV-patients with low CD4 counts. It has anti-malarial activity with prophylactic efficacy that is comparable to SP (30-90%). Daily TMPS is recommended as malaria prophylaxis in pregnant women with HIV in many African countries (including Cameroon) but malaria infection rates are high even when medication compliance is excellent; thus, new and improved options are urgently needed. Azithromycin (AZ) is a macrolide antibiotic with activity against malaria, a good safety profile in pregnancy and proven utility as a part of combination malaria prevention regimens (such as SP-AZ). It also has activity against sexually transmitted infections (STI) and perinatal pathogens, including chlamydia (CT), gonorrhea (GC), syphilis and GBS (Streptococcus agalactiae or Group B Streptococcus), a potential but understudied contributor to high rates of newborn sepsis and death in Africa. SP-AZ prophylaxis in HIV-uninfected pregnant women has been reported to reduce prevalence of low birth weight (RR 0.74, 95% confidence interval (CI) 0.6-0.9) and preterm delivery (RR 0.66, 95% CI 0.48-0.91) compared to SP alone.
Thus, the central hypothesis is that a TMPS-AZ combination will be more effective than standard TMPS malaria prophylaxis in pregnant women with HIV, and that it will also decrease STI coinfection. Investigators plan a test-of-concept of the central hypothesis by conducting a double blinded, Phase II randomized controlled trial (RCT).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Azithromycin/TMPS | Active Comparator | Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit. TMPS double strength 1 tablet po daily. |
|
| Placebo/TMPS | Placebo Comparator | Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit. TMPS double strength 1 tablet po daily. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Azithromycin/TMPS | Drug | 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit |
|
| Measure | Description | Time Frame |
|---|---|---|
| Plasmodium Falciparum Peripheral Parasitemia | P. falciparum detected by microscopy or polymerase chain reaction (PCR) | At end of pregnancy (>35 weeks) or at delivery |
| Proportion With Composite STI Outcome | Including chlamydia (NAAT (nucleic acid amplification test) positive) , gonorrhea (NAAT positive), syphilis (non-treponemal and treponemal test positive) infections. | will be measured in both groups (>35 weeks) or at delivery |
| Measure | Description | Time Frame |
|---|---|---|
| Low Birthweight (<2500 Grams) | Neonatal weight measured with digital scale | at birth |
| Proportion With Adverse Birth Outcomes | Composite measure: low infant birthweight (<2500 grams), miscarriage (<28 weeks), preterm delivery (<37 weeks), small for gestational age (SGA), congenital anomaly detected on surface examination, early neonatal mortality (within 7 days of birth) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jodie A Dionne-Odom, MD | University of Alabama at Birmingham | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39324693 | Derived | Pons-Duran C, Wassenaar MJ, Yovo KE, Marin-Carballo C, Briand V, Gonzalez R. Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women. Cochrane Database Syst Rev. 2024 Sep 26;9(9):CD006689. doi: 10.1002/14651858.CD006689.pub3. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Azithromycin/TMPS | Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit. TMPS double strength 1 tablet po daily. Azithromycin/TMPS: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit |
| FG001 | Placebo/TMPS | Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit. TMPS double strength 1 tablet po daily. Placebo/TMPS: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Azithromycin/TMPS | Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit. TMPS double strength 1 tablet po daily. Azithromycin/TMPS: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit |
| BG001 | Placebo/TMPS |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Plasmodium Falciparum Peripheral Parasitemia | P. falciparum detected by microscopy or polymerase chain reaction (PCR) | Posted | Count of Participants | Participants | At end of pregnancy (>35 weeks) or at delivery |
|
From enrollment during the 2nd trimester through delivery
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Azithromycin/TMPS | Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit. TMPS double strength 1 tablet po daily. Azithromycin/TMPS: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Jodie Dionne | UAB | 2059756530 | jdionne@uabmc.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP_ICF | Yes | Yes | Yes | Study Protocol, Statistical Analysis Plan, and Informed Consent Form | Sep 5, 2018 | Apr 6, 2022 | Prot_SAP_ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D012749 | Sexually Transmitted Diseases |
| ID | Term |
|---|---|
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015662 | Trimethoprim, Sulfamethoxazole Drug Combination |
| ID | Term |
|---|---|
| D013420 | Sulfamethoxazole |
| D000096926 | Benzenesulfonamides |
| D013449 | Sulfonamides |
| D000577 | Amides |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo/TMPS | Drug | 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit |
|
|
| Birth outcomes will be measured at birth for all outcomes except early neonatal mortality defined as within 7 days of birth. Early neonatal mortality will be assessed at a six week follow up phone call. |
| Maternal Adherence to the Prophylactic Regimen | Directly observed therapy (DOT) in clinic for the 1st dose of study medication. Self-report and pill count will be used to assess adherence and maternal tolerability for study medications taken at home from the time of enrollment until delivery. At each follow up visit and at delivery, participants will complete a medication adherence survey. They will self-report adherence to the 3 day study regimen (AZ or placebo). | Adherence of study medication taken at home will be documented from the date of randomization until the time of delivery, assessed up to 42 weeks. |
| Proportion of Participants With Symptomatic Malaria | Fever and positive malaria test (rapid diagnostic test) at routine visits or sick call visits or maternal report of malaria diagnosis. | From the date of randomization until the time of delivery, assessed up to 42 weeks. |
| Proportion With Placental Malaria | Placentas will be collected on a subset of women and impression smear will be used to assess for malaria infection | At delivery |
| Proportion With Maternal Anemia and Severe Maternal Anemia | anemia defined as hemoglobin <11 g/dL, severe anemia defined as hemoglobin <7 g/dL. | At the end of pregnancy (>35 weeks) or at delivery |
| Composite STI Measure (Including All STI Tests) | Proportion of women with GC/CT (by NAAT), syphilis (by serology), Mycoplasma genitalium (NAAT). | After 35 weeks GA or at delivery |
| GBS Colonization | anogenital GBS colonization detected by NAAT (PCR) | at or near term or at delivery |
Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit. TMPS double strength 1 tablet po daily. Placebo/TMPS: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Median | Inter-Quartile Range | years |
|
| Sex: Female, Male | All pregnant females | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Cameroon | Number | participants |
|
|
|
| Primary | Proportion With Composite STI Outcome | Including chlamydia (NAAT (nucleic acid amplification test) positive) , gonorrhea (NAAT positive), syphilis (non-treponemal and treponemal test positive) infections. | Posted | Count of Participants | Participants | will be measured in both groups (>35 weeks) or at delivery |
|
|
|
| Secondary | Low Birthweight (<2500 Grams) | Neonatal weight measured with digital scale | Posted | Count of Participants | Participants | at birth |
|
|
|
| Secondary | Proportion With Adverse Birth Outcomes | Composite measure: low infant birthweight (<2500 grams), miscarriage (<28 weeks), preterm delivery (<37 weeks), small for gestational age (SGA), congenital anomaly detected on surface examination, early neonatal mortality (within 7 days of birth) | Posted | Count of Participants | Participants | Birth outcomes will be measured at birth for all outcomes except early neonatal mortality defined as within 7 days of birth. Early neonatal mortality will be assessed at a six week follow up phone call. |
|
|
|
| Secondary | Maternal Adherence to the Prophylactic Regimen | Directly observed therapy (DOT) in clinic for the 1st dose of study medication. Self-report and pill count will be used to assess adherence and maternal tolerability for study medications taken at home from the time of enrollment until delivery. At each follow up visit and at delivery, participants will complete a medication adherence survey. They will self-report adherence to the 3 day study regimen (AZ or placebo). | Posted | Count of Participants | Participants | Adherence of study medication taken at home will be documented from the date of randomization until the time of delivery, assessed up to 42 weeks. |
|
|
|
| Secondary | Proportion of Participants With Symptomatic Malaria | Fever and positive malaria test (rapid diagnostic test) at routine visits or sick call visits or maternal report of malaria diagnosis. | Posted | Count of Participants | Participants | From the date of randomization until the time of delivery, assessed up to 42 weeks. |
|
|
|
| Secondary | Proportion With Placental Malaria | Placentas will be collected on a subset of women and impression smear will be used to assess for malaria infection | Posted | Count of Participants | Participants | At delivery |
|
|
|
| Secondary | Proportion With Maternal Anemia and Severe Maternal Anemia | anemia defined as hemoglobin <11 g/dL, severe anemia defined as hemoglobin <7 g/dL. | Posted | Count of Participants | Participants | At the end of pregnancy (>35 weeks) or at delivery |
|
|
|
| Secondary | Composite STI Measure (Including All STI Tests) | Proportion of women with GC/CT (by NAAT), syphilis (by serology), Mycoplasma genitalium (NAAT). | Posted | Count of Participants | Participants | After 35 weeks GA or at delivery |
|
|
|
| Secondary | GBS Colonization | anogenital GBS colonization detected by NAAT (PCR) | Posted | Count of Participants | Participants | at or near term or at delivery |
|
|
|
| 0 |
| 155 |
| 0 |
| 155 |
| 0 |
| 155 |
| EG001 | Placebo/TMPS | Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit. TMPS double strength 1 tablet po daily. Placebo/TMPS: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit | 0 | 153 | 0 | 153 | 0 | 153 |
Not provided
Not provided
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009930 |
| Organic Chemicals |
| D013424 | Sulfanilamides |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D014295 | Trimethoprim |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |